ChromaDex (NASDAQ:CDXC) Shares Pass Above 200-Day Moving Average – Should You Sell?

ChromaDex Co. (NASDAQ:CDXC) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $4.22 and traded as high as $5.55. ChromaDex shares last traded at $5.30, with a volume of 256,732 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts have issued reports on CDXC shares. StockNews.com raised ChromaDex from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, December 25th. Roth Mkm upped their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, HC Wainwright raised their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th.

ChromaDex Stock Performance

The stock has a fifty day moving average price of $6.25 and a two-hundred day moving average price of $4.23. The firm has a market capitalization of $420.87 million, a P/E ratio of 551.55 and a beta of 2.15.

ChromaDex (NASDAQ:CDXC) last issued its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The company had revenue of $25.58 million for the quarter, compared to analysts’ expectations of $23.70 million. During the same period in the prior year, the company earned ($0.01) earnings per share. As a group, research analysts anticipate that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.

Insider Activity

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the transaction, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. The trade was a 13.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On ChromaDex

A number of hedge funds have recently made changes to their positions in CDXC. The Manufacturers Life Insurance Company acquired a new stake in ChromaDex in the 2nd quarter valued at approximately $31,000. Merriman Wealth Management LLC acquired a new position in shares of ChromaDex during the second quarter valued at $32,000. FMR LLC bought a new stake in shares of ChromaDex during the third quarter valued at about $55,000. Marshall Wace LLP acquired a new stake in ChromaDex in the second quarter worth about $56,000. Finally, SG Americas Securities LLC bought a new position in ChromaDex in the 3rd quarter valued at about $61,000. Institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.